ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » South Carolina » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in South Carolina

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
RONALD LITTLEFIELD MD

Cardiovascular Disease

15,671

$900K

401
280 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

28%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 26%

$57
Average prescription price

Avg: $56

RAMON SY MD

Cardiovascular Disease

13,601

$736K

443
306 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 26%

$54
Average prescription price

Avg: $56

NAVEEN SAXENA MD FACC

Cardiovascular Disease

12,634

$602K

873
586 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 26%

$48
Average prescription price

Avg: $56

ANSERMO ARTHUR M.D.

Cardiovascular Disease

11,412

$693K

805
661 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 26%

$61
Average prescription price

Avg: $56

DAVID CUNDEY M.D.

Cardiovascular Disease

10,411

$696K

730
631 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 26%

$67
Average prescription price

Avg: $56

GREGORY EAVES M.D.

Cardiovascular Disease

10,080

$595K

769
677 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 26%

$59
Average prescription price

Avg: $56

MARK CIMINELLI M.D.

Cardiovascular Disease

9,663

$423K

1127
867 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 26%

$44
Average prescription price

Avg: $56

JAY KALAN MD

Cardiovascular Disease

9,506

$674K

899
842 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 26%

$71
Average prescription price

Avg: $56

VIPULKUMAR SHAH M.D.

Cardiovascular Disease

8,614

$328K

972
703 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 26%

$38
Average prescription price

Avg: $56

MARK KRZYSTON M.D.

Cardiovascular Disease

8,597

$455K

547
479 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 26%

$53
Average prescription price

Avg: $56

VASANT PATEL M.D.

Cardiovascular Disease

8,460

$462K

1087
870 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 26%

$55
Average prescription price

Avg: $56

DEEPAK SHAH M.D.

Cardiovascular Disease

8,384

$404K

994
715 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 26%

$48
Average prescription price

Avg: $56

LAWRENCE STROUD MD

Cardiovascular Disease

7,651

$425K

198
181 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 26%

$56
Average prescription price

Avg: $56

DAVID IKE M.D.

Cardiovascular Disease

7,515

$276K

609
496 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 26%

$37
Average prescription price

Avg: $56

TIMOTHY MALINOWSKI MD

Cardiovascular Disease

7,201

$377K

509
434 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 26%

$52
Average prescription price

Avg: $56

ALAN BLAKER M.D.

Cardiovascular Disease

7,045

$459K

498
381 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 26%

$65
Average prescription price

Avg: $56

JOHN SHARP MD

Cardiovascular Disease

6,997

$575K

787
745 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 26%

$82
Average prescription price

Avg: $56

GEORGE CASTRO MD

Cardiovascular Disease

6,756

$292K

539
403 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 26%

$43
Average prescription price

Avg: $56

STEVEN JOHNSON M.D.

Cardiovascular Disease

6,720

$350K

536
443 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 26%

$52
Average prescription price

Avg: $56

PRADEEP SINGH M.D.

Cardiovascular Disease

6,302

$276K

810
645 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 26%

$44
Average prescription price

Avg: $56

AMY EPPS MD

Cardiovascular Disease

6,255

$397K

496
419 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 26%

$64
Average prescription price

Avg: $56

BRAD SIMPSON M.D.

Cardiovascular Disease

6,250

$411K

612
508 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 26%

$66
Average prescription price

Avg: $56

DAVID RODAK M.D.

Cardiovascular Disease

6,110

$327K

662
550 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 26%

$53
Average prescription price

Avg: $56

MICHAEL PAYNE M.D.

Cardiovascular Disease

6,096

$375K

586
504 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 26%

$62
Average prescription price

Avg: $56

TALAL BAKI MD

Cardiovascular Disease

5,924

$189K

893
709 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 26%

$32
Average prescription price

Avg: $56

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank